KRYS: חוב לטווח קצר של החברה Krystal Biotech, Inc.

The current volume of short-term loans correlates with the commercialization of Vyjuvek and the management of cash flows for Krystal Biotech, Inc. (KRYS). The value of 0.00 reflects this status, confirming the company's position as an innovator in the treatment of rare skin pathologies. The business's success relies on the authority of Krish Krishnan's team, whose R&D competencies ensured the market launch of the first topical gene therapy.

This indicator measures the aggregate volume of borrowed funds with a maturity horizon of up to one year, allowing for an assessment of current liquidity and the risk of working capital deficits. By analyzing short-term balance sheet liabilities on GURU.Markets, an investor can benchmark the debt load of Krystal Biotech, Inc. (KRYS) against industry peers to evaluate the company's ability to fund the maintenance of the ANCOR sterile plant without a critical increase in leverage.